Six detained for abuse of patients in Bulgaria nursing home
SOFIA (Reuters) -Six people have been arrested in a Bulgarian village on suspicion of beating and drugging patients in a private nursing home for older people and those with dementia or other mental health problems, authorities said on Monday.
As elsewhere in Europe, incomes in Bulgaria have failed to keep pace with the rising costs of elderly and nursing care, and a few providers have exploited vulnerable patients with sub-standard or even abusive levels of care.
"The scariest thing we saw was people who were subjected to constant physical abuse - tied up, beaten, there is also evidence of drugging," Ivan Krastev, deputy minister of labour and social policy, told Nova TV.
On Friday, police raided a hospice with 75 residents in the central village of Yagoda, arresting five people on suspicion of mistreating patients and another on Sunday.
They are charged with unlawful imprisonment and obstruction of free movement, failure to provide due assistance to a person in danger, physical violence, and causing bodily harm, district prosecutor Tanya Dimitrova told reporters on Monday.
Eleven patients were taken to a nearby state hospital, while the remaining 64 were either taken in by relatives or accommodated in state-run facilities.
Bulgarian media reported that some patients had been found with their feet tied, under the influence of narcotics or locked in rooms without proper hygiene, bedding or contact with the outside world.
"They lock us up like dogs. They give us two slices of bread and in this heat they don't open the door to let air in, as they're afraid we'll escape," 70-year-old patient Milka Raeva told BTV TV.
"They were four very difficult years. God helped me. Many people died hungry, without doctors, with wounds, tied up."
Bulgarian media reported that the facility was charging 990 levs ($580) per month per room. Another illegal nursing home in Govedartsi with 23 patients was closed down on Monday.
($1 = 1.7104 leva)

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
7 minutes ago
- Yahoo
'I'm not a porn star': 'Diddy' accuser says she asked to stop sex performances
By Luc Cohen NEW YORK (Reuters) -One of Sean "Diddy" Combs' former girlfriends testified on Monday in the hip-hop mogul's sex trafficking trial that she told him in text messages that she felt mistreated in their relationship and asked to stop taking part in sexual performances with other men. "I'm not a porn star. I'm not an animal," the woman, testifying under the pseudonym Jane to protect her privacy, wrote Combs on October 16, 2023, according to a text message she read aloud in court. "It's loveless for me and nothing satisfies you and you always push me to do more and more." The messages could bolster prosecutors' contention that Combs, 55, for two decades coerced women to take part in the sexual performances, sometimes known as "Freak Offs," against their will. Combs is charged with using physical force and threatening to cut off financial support to get women to take part in the drug-fueled, sometimes days-long performances in hotel rooms while he watched. Combs, the founder of Bad Boy Records, has pleaded not guilty to charges of racketeering conspiracy and sex trafficking. His lawyers have acknowledged that Combs was occasionally abusive in domestic relationships, but say the women who took part in Freak Offs did so consensually. Jane, the third alleged sex abuse victim of Combs to testify at his trial in Manhattan federal court, told jurors last week that she was "head over heels" for Combs at the outset of their relationship, which lasted from 2021 through 2024. She testified that most of the time they spent together involved sex performances with male escorts in hotel rooms, even though she wanted to go on dates with just Combs. She said Combs - whose net worth Forbes estimated at above $1 billion in 2022 - threatened to stop paying her rent when she said she wanted to stop having sex with other men. Combs' defense lawyers are due to cross-examine Jane later this week. The trial is in its fifth week. Combs could face life in prison if convicted on all counts. Also known throughout his career as Puff Daddy and P. Diddy, Combs turned artists like Notorious B.I.G. and Usher into stars, elevating hip-hop in American culture and becoming a billionaire in the process.

Yahoo
7 minutes ago
- Yahoo
US Justice Department reportedly shrinks foreign bribery investigation team
-- The team at the U.S. Justice Department responsible for investigating allegations of foreign bribery has significantly shrunk, according to a Reuters report on Monday. This comes as President Donald Trump's administration reassesses its enforcement of an anti-corruption law that has been in place for decades. The Department of Justice's Fraud Section, which is in charge of enforcing the anti-bribery law, has been reduced to around 15 prosecutors. This is a substantial decrease from the 32 prosecutors reported in January, as stated on the department's website, the report said. This reduction follows an executive order issued by President Trump in February. The order called for a temporary halt in the enforcement of the Foreign Corrupt Practices Act (FCPA), a law enacted in 1977. The FCPA prohibits companies operating in the U.S. from bribing foreign officials and is considered a fundamental part of federal efforts to fight corruption. Related articles US Justice Department reportedly shrinks foreign bribery investigation team SEC progresses toward DOGE goals, eyes voluntary workforce reductions Trump signs orders to enhance drone defenses, support supersonic travel


Medscape
22 minutes ago
- Medscape
Merck's Potential Blockbuster Cholesterol Pill Succeeds in Late-stage Studies
(Reuters) -Merck's oral cholesterol pill succeeded in two late-stage studies, marking a win for the drugmaker as it focuses on the development of growth drivers beyond its cancer drugs and vaccines. The company is searching for its next blockbuster candidate as its major revenue driver, Keytruda, is expected to lose patent protection by the end of the decade. Merck's non-statin cholesterol drug, enlicitide decanoate, is being tested for the treatment of hyperlipidemia, a condition that causes elevated buildup of fat in the blood vessels and can lead to heart attacks and strokes. Enlicitide works by blocking PCSK9, a protein that plays a crucial role in regulating cholesterol levels, while statins block an enzyme the liver uses to make cholesterol. BMO Capital Markets analyst Evan Seigerman said Merck's drug could potentially provide a "multi-billion dollar opportunity" that expands the PCSK9 market beyond current injectable therapies. The drug showed meaningful reductions in LDL-C cholesterol, commonly referred to as "bad cholesterol", when compared to placebo and other oral non-statin therapies, Merck said. However, Leerink analysts have noted that Astrazeneca's AZD0780 is a "credible threat" as it has shown a 50.7% reduction in LDL-C levels during a trial. Merck has not given the details on LDL-C reduction for enlicitide. The drug was tested in patients who have a history of, or are at risk for a type of heart disease, and were treated with a statin. Shares of Merck were up 2% in premarket trading. Verve Therapeutics is also developing a gene therapy to reduce high cholesterol levels, which is expected to be used in combination with other drugs. (Reporting by Christy Santhosh in Bengaluru; Editing by Shinjini Ganguli)